Exemption scope for anti-tuberculosis formulations excludes a three-drug combination containing Rifampicin, Pyrazinamide and Isoniazid.

A three-drug anti-tuberculosis formulation containing Rifampicin, Pyrazinamide and Isoniazid fell outside Notification No. 44/90-C.E. (N.T.), because the exemption covered Rifampicin and formulations of Rifampicin with Isoniazid only. On that reading, Montorip Capsule did not satisfy the notification's scope and was not eligible for exemption. The Tribunal noted that relief already granted for other products was not in dispute, and the exemption issue was confined to this capsule.

---

---

Issues: Whether Montorip Capsule, being a formulation containing Rifampicin, Pyrazinamide and Isoniazid, was eligible for exemption under Notification No. 44/90-C.E. (N.T.) dated 1-11-1990.

Analysis: The notification covered Rifampicin and formulations of Rifampicin with Isoniazid only. Montorip Capsule contained a three-drug combination of Rifampicin, Pyrazinamide and Isoniazid, which fell outside the scope of the exemption. The relief already granted for the other products was not in dispute before the Tribunal.

Conclusion: The exemption was not available for Montorip Capsule, and the appeal failed to that extent.

---